Prostate Cancer Care Disparity Analysis Project (ProGAP)
NCT ID: NCT06612034
Last Updated: 2025-07-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
400 participants
OBSERVATIONAL
2025-03-10
2025-10-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The primary question it addresses is: Are the standards of care for prostate cancer uniformly applied across different geographic regions worldwide? To achieve this, we will recruit physicians specializing in the diagnosis and treatment of prostate cancer from a diverse array of countries within these income classifications. Participants will complete a 17-question online survey.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prostate Cancer Study of Patient Experiences
NCT07096596
Prostatic Cancer Versus Androgen Deficiency
NCT02235142
Prostate Specific Antigen Levels of Individuals Living in Rural Areas
NCT06900348
Quality of Life, Functional and Cognitive Outcomes in Patients With Metastatic Hormone-Sensitive Prostate Cancer
NCT07181122
Prognostic Factors in Prostate Cancer for Patients Treated by Watchful Waiting
NCT03912883
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Objectives:
1. To systematically gather and analyze data on current diagnostic methods, treatment modalities, and management practices for prostate cancer from a wide range of countries and healthcare settings.
2. To identify and quantify disparities in access to and availability of standard care, novel treatments, and supportive services for patients with prostate cancer.
3. To evaluate the adherence levels to both international and national guidelines in prostate cancer treatment across diverse healthcare systems.
Methods:
The ProGAP survey will be distributed internationally to healthcare professionals, including urologists, uro-oncologists, medical oncologists, and radiation oncologists, who are actively involved in prostate cancer care. The survey will comprehensively cover demographic details, clinical practice environment, patient demographics and stages managed, guideline adherence, availability and use of diagnostic and treatment options, and multidisciplinary care approaches. A survey and a consent form will be sent to study participants in addition to written information about the study. Completing surveys will take 10-12 minutes. Participants will complete a 17-question online survey. The first part of the form includes questions about demographics and hospital characteristics. The second part contains questions about prostate cancer diagnosis, treatment, and management practices. Participation in this study is entirely voluntary and anonymous. Neither sensitive personal data nor contact information will be collected during the research. This research does not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors, and the investigators declare that they do not have any conflict of interest with the work.
Data Analysis Plan:
Statistical analyses will employ both descriptive and inferential statistics to interpret the survey data. Comparative analyses will be conducted to uncover disparities across different regions and healthcare settings. Advanced statistical methods, such as regression analysis, may be utilized to explore factors associated with variations in care practices and outcomes.
Expected Impact:
By elucidating the disparities in prostate cancer care worldwide, ProGAP aims to stimulate policy changes, guide improvements in clinical practice, and foster international collaborations to enhance the quality of care and outcomes for patients with prostate cancer globally. Insights gained from this project are anticipated to inform stakeholders, including healthcare providers, policymakers, and patient advocacy groups, about critical areas for intervention and improvement.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Healthcare professionals for prostate cancer
Healthcare professionals actively engaged in prostate cancer treatment, including urologists, uro-oncologists, medical oncologists, and radiation oncologists
No Intervention: Observational Cohort
No Intervention: Observational Cohort
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
No Intervention: Observational Cohort
No Intervention: Observational Cohort
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ankara University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Yüksel Ürün
Professor doctor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yüksel Ürün
Role: STUDY_DIRECTOR
Ankara University
Deborah Mukherji
Role: STUDY_DIRECTOR
Clemenceau Medical Center Hospital Dubai
Mohammed Shahait
Role: STUDY_DIRECTOR
Al Zahra Hospital Dubai
Luis Castelo Branco
Role: STUDY_DIRECTOR
IOSI Oncologist Institute of Southern Switzerland
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ankara University Faculty of Medicine
Ankara, Ankara, Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ANKARA-UNIVERSITY-YURUN-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.